Residual neuromuscular blockade in critical care

Critical Care Nurse

Volumn 32, Issue 3, 2012, Pages

  Wilson, Jason ^a   Collins, Angela S ^a,b   Rowan, Brea O ^a  

^a Princeton Baptist Birmingham   (United States)

^b UNIVERSITY OF ALABAMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROMUSCULAR BLOCKING AGENT;

ARTICLE; DRUG EFFECT; DRUG INTERACTION; HUMAN; INTENSIVE CARE; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR SYNAPSE; NURSING; NURSING ASSESSMENT; PERIOPERATIVE NURSING; RISK FACTOR;

CRITICAL CARE; DRUG INTERACTIONS; HUMANS; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR BLOCKING AGENTS; NEUROMUSCULAR JUNCTION; NURSING ASSESSMENT; PERIOPERATIVE NURSING; RISK FACTORS;

EID: 84864856713     PISSN: 02795442     EISSN: 19408250     Source Type: Journal    
DOI: 10.4037/ccn2012107     Document Type: Article

References (39)

1. Corso L. Train-of-four results and observed muscle movement in children during continuous neuromuscular blockade. Crit Care Nurse. 2008;28(3):30-39. http://ccn .aacnjournals.org/content/28/3/30.full. Accessed March 5, 2012.
2. Drain CB. Neuromuscular blocking agents. In: Drain CB, Odom-Forren J, eds. Perianesthesia Nursing: A Critical Care Approach. St Louis, MO: Saunders Elsevier; 2009:318-337.
3. Mort TC. Emergency tracheal intubation: complications associated with repeated laryngoscopic attempts. Anesth Analg. 2004; 99:606-613.
4. Claudius C, Garvey LH, Viby-Mogensen J. The undesirable effects of neuromuscular blocking drugs. Anaesthesia. 2009;64(suppl 1):10-21.
5. Cammu G, De Witte J, De Veylder J, et al. Postoperative residual paralysis in outpatients versus inpatients. Anesth Analg. 2006; 102(2):426-429.
6. Maybauer DM, Geldner G, Blobner M, et al. Incidence and duration of residual paralysis at the end of surgery after multiple administrations of cisatracurium and rocuronium. Anaesthesia. 2007;62(1):12-17.
7. Murphy GS, Szokol JW, Franklin M, Marymont JH, Avram MJ, Vender JS. Postanesthesia care unit recovery times and neuromuscular blocking drugs: a prospective study of orthopedic surgical patients randomized to receive pancuronium or rocuronium. Anesth Analg. 2004;98:193-200.
8. Yip P, Hannam J, Cameron A, Campbell D. Incidence of residual neuromuscular blockade in a post-anesthetic care unit. Anaesth Intensive Care. 2010;38(1):91-95. http:// www.aaic.net.au/Document/?D=2007578. Accessed March 5, 2012.
9. Jonsson Fagerlund M, Dabrowski M, Eriksson L. Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009;110(6):1244-1252.
10. Burton S, Alexander E. Avoiding the pitfalls and ensuring the safety of sustained neuromuscular blockade. AACN Adv Crit Care. 2006;17(3):239-245.
11. Westfall TC, Westfall DP. Neurotransmission: the autonomic and somatic motor nervous systems. In: Burton LL, Lazo JS, Parker KL, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill Co Inc; 2005:137-182.
12. Taylor P. Agents acting at the neuromuscular junction and autonomic ganglia: introduction. In: Burton LL, Lazo JS, Parker KL. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill Co Inc; 2005:217-236.
13. Deglin J, Vallerand A. Davis's Drug Guide for Nursing. 12th ed. Philadelphia, PA: FA Davis Co; 2011.
14. Hayes A, Breslin D, Reid J, Mirakhur K. Comparison of recovery following rapacuronium, with and without neostigmine, and succinylcholine. Anaesthesia. 2000;55(9):859-863.
15. Kopman A, Eikermann M. Antagonism of non-depolarizing neuromuscular block: current practice. Anaesthesia. 2009;64(suppl 1):22-30.
16. Hogg RMG, Mirakhur RK. Reversal of neuromuscular blockade: current concepts and future developments. J Anaesthesiol Clin Pharmacol. 2009;25(4):403-412.
17. Lee C, Katz RL. Clinical implications of new neuromuscular concepts and agents: so long, neostigmine! So long, sux! J Crit Care. 2009;24:43-49.
18. Mirakhur R. Sugammadex in clinical practice. Anaesthesia. 2009;64(suppl 1):45-54.
19. Illman HL, Laurila P, Antila H, Meretoja OA, Alahuhta S, Olkkola KT. The duration of residual neuromuscular block after admini stration of neostigmine or sugammadex at two visible twitches during trainof-four monitoring. Anesth Analg. 2011;112(1):63-68.
20. Foster J, Clark A. Functional recovery after neuromuscular blockade in mechanically ventilated critically ill patients. Heart Lung. 2006;35(3):178-189.
21. Zhang B, Hepner DL, Tran MH, Friedman M, Korn JR, Menzin J. Neuromuscular blockade, reversal agent use, and operating room time: retrospective analysis of US inpatient surgeries. Curr Med Res Opin. 2009; 25(4):943-950.
22. American Society of Anesthesiologists Task Force on Postanesthetic Care. Practice guidelines for postanesthetic care. Anesthesiology. 2002;96(3):742-752.
23. Claudius C, Viby-Mogensen J. Acceleromyography for use in scientific and clinical practice. Anesthesiology. 2008;108(6):1117-1140.
24. Nagelhout J, Plaus K. Neuromuscular blocking agents, reversal agents, and their monitoring. In: Nurse Anesthesia. 4th ed. St Louis, MO: Saunders Elsevier; 2010:179-202.
25. Fuchs-Buder T, Schreiber JU, Meistelman C. Monitoring neuromuscular block: an update. Anaesthesia. 2009;64(suppl 1):82-89.
26. American Society of PeriAnesthesia Nurses. Clinical guideline for the prevention of unplanned perioperative hypothermia. http://www.aspan.org/ClinicalPractice /ClinicalGuidelines/Normothermia/tabid| /5599/Default.aspx. Accessed February 9, 2010.
27. Burns SM, Wojnakowski M, Piotrowski K, Caraffa G. Unintentional hypothermia: implications for perianesthesia nurses. J Perianesth Nurs. 2009;24(3):167-176.
28. Heier T, Caldwell JE. Impact of hypothermia on the response to neuromuscular blocking drugs. Anesthesiology. 2006;104:1070-1080.
29. Heier T, Clough D, Wright P, Sharma M, Sessler D, Caldwell J. The influence of mild hypothermia on the pharmacokinetics and time course of action of neostigmine in anesthetized volunteers. Anesthesiology. 2002; 97(1):90-95.
30. Harris A, Welliver M, Redfern R, Kalynych N, McDonough J. Orthopaedic surgery implications of a novel encapsulation process that improves neuromuscular blockade and reversal. Internet J Orthop Surg. 2007;7(2). http://www.ispub.com/ostia /index.php?xmlFilePath=journals/ijos /vol7n2/nmb.xml. Accessed March 5, 2012.
31. Abrams A, Lammon C, Pennington S. Clinical Drug Therapy: Rationale for Nursing Practice. 9th ed. Philadelphia, PA: Walters Kluwer/Lippincott Williams & Wilkins; 2009.
32. Caldwell JE, Heier T, Wright PMC, et al. Temperature-dependent pharmacokinetics and pharmacodynamics of vecuronium. Anesthesiology. 2000;92(1):84-93.
33. Hooper V. Care of the patient with thermal imbalance. In: Drain CB, Odom-Forren J, eds. Perianesthesia Nursing: A Critical Care Approach. St Louis, MO: Saunders Elsevier; 2009:748-759.
34. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:391-396.
35. Beaufort AM, Wierda JM, Belopavlovic M, Nederveen PJ, Kleef UW, Agoston S. The influence of hypothermia (surface cooling) on the time-course of action and on the pharmacokinetics of rocuronium in humans. Eur J Anaesthesiol Suppl. 1995;11:95-106.
36. Donati F, Vevan D. Neuromuscular blocking agents. In: Barash PG, Cullen BF, Stoelting RK, Cahalan MK, Stock MC, eds. Clinical Anesthesia. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009: 498-530.
37. Kindler CH, Verotta D, Gray AT, Gropper MA, Yost CS. Additive inhibition of nicotinic acetylcholine receptors by corticosteroids and the neuromuscular blocking drug vecuronium. Anesthesiology. 2000;92: 821-832.
38. Jaramillo KS, Scruth E, Cheng E. Prolonged paralysis and apnea after receiving a neuromuscular blocking agent: what nurses should know. Am J Crit Care. 2009;18(6):588-592.
39. Ramachandran SK, O'Brien D. Counterpoint: residual neuromuscular blockade in the PACU-a continuing serious problem. J Perianesth Nurs. 2010;25(2):121-123.